MA55766A - Nanoparticules lipidiques - Google Patents

Nanoparticules lipidiques

Info

Publication number
MA55766A
MA55766A MA055766A MA55766A MA55766A MA 55766 A MA55766 A MA 55766A MA 055766 A MA055766 A MA 055766A MA 55766 A MA55766 A MA 55766A MA 55766 A MA55766 A MA 55766A
Authority
MA
Morocco
Prior art keywords
lipid nanoparticles
nanoparticles
lipid
Prior art date
Application number
MA055766A
Other languages
English (en)
French (fr)
Inventor
James Heyes
Adam Judge
Kieu Mong Lam
Alan D Martin
Original Assignee
Genevant Sciences Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genevant Sciences Gmbh filed Critical Genevant Sciences Gmbh
Publication of MA55766A publication Critical patent/MA55766A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nanotechnology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
MA055766A 2019-04-26 2020-04-24 Nanoparticules lipidiques MA55766A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962839452P 2019-04-26 2019-04-26
US201962867098P 2019-06-26 2019-06-26

Publications (1)

Publication Number Publication Date
MA55766A true MA55766A (fr) 2022-03-02

Family

ID=72941858

Family Applications (1)

Application Number Title Priority Date Filing Date
MA055766A MA55766A (fr) 2019-04-26 2020-04-24 Nanoparticules lipidiques

Country Status (8)

Country Link
US (1) US20220168222A1 (OSRAM)
EP (1) EP3959314A4 (OSRAM)
JP (1) JP2022530018A (OSRAM)
CN (1) CN114026233A (OSRAM)
AU (1) AU2020262437A1 (OSRAM)
CA (1) CA3137450A1 (OSRAM)
MA (1) MA55766A (OSRAM)
WO (1) WO2020219941A1 (OSRAM)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA202191315A1 (ru) * 2018-11-09 2021-09-08 Арбутус Биофарма Корпорэйшн Катионные липиды, содержащие кремний
CN114901360A (zh) 2019-12-20 2022-08-12 库瑞瓦格股份公司 用于递送核酸的新型脂质纳米颗粒
US12023376B1 (en) 2020-04-17 2024-07-02 Triad National Security, Llc Conserved region T cell vaccines for coronavirus and methods of use
CN115768438A (zh) * 2020-07-10 2023-03-07 盖纳万科学有限公司 用于向肺递送治疗剂的脂质纳米颗粒
WO2022023284A1 (en) 2020-07-27 2022-02-03 Anjarium Biosciences Ag Compositions of dna molecules, methods of making therefor, and methods of use thereof
CZ310613B6 (cs) 2020-09-23 2026-01-28 Ústav organické chemie a biochemie AV ČR, v. v. i. Lipidoidy pro transfekci nukleových kyselin a jejich použití
KR20230118715A (ko) 2020-10-14 2023-08-11 조지 메이슨 리서치 파운데이션 인코포레이티드 이온화 가능 지질 및 이의 제조 및 사용 방법
US11771652B2 (en) 2020-11-06 2023-10-03 Sanofi Lipid nanoparticles for delivering mRNA vaccines
CA3200234A1 (en) 2020-11-25 2022-06-02 Daryl C. Drummond Lipid nanoparticles for delivery of nucleic acids, and related methods of use
CN117479963A (zh) * 2020-12-18 2024-01-30 盖纳万科学有限公司 Peg脂质和脂质纳米粒子
WO2022198229A1 (en) * 2021-03-17 2022-09-22 Board Of Regents Of The University Of Nebraska Lipid nanoparticle formulations and methods of use thereof
WO2022221736A2 (en) 2021-04-16 2022-10-20 Genentech, Inc. Optimized tlr7 ligands and uses thereof
CZ310443B6 (cs) 2021-07-19 2025-06-25 Ústav organické chemie a biochemie AV ČR, v. v. i. Cyklohexanové lipidoidy pro transfekci nukleových kyselin a jejich použití
CN117940158A (zh) 2021-09-03 2024-04-26 库瑞瓦格欧洲公司 用于核酸递送的包含磷脂酰丝氨酸的新型脂质纳米颗粒
EP4419677A4 (en) 2021-10-18 2025-09-24 Flagship Pioneering Innovations Vii Llc DNA COMPOSITIONS AND RELATED METHODS
KR20230061895A (ko) * 2021-10-29 2023-05-09 주식회사 아이큐어비앤피 지질 나노입자 및 세포 투과성을 갖는 신규 펩타이드의 복합체
CN117203186A (zh) * 2022-05-13 2023-12-08 南方科技大学 一种含有二硫键的脂质化合物及其组合物
WO2023218431A1 (en) 2022-05-13 2023-11-16 BioNTech SE Rna compositions targeting hiv
EP4529472A1 (en) 2022-05-23 2025-04-02 Logicbio Therapeutics, Inc. Gene therapy compositions and methods of use thereof
EP4531819A2 (en) 2022-05-25 2025-04-09 Akagera Medicines, Inc. Lipid nanoparticles for delivery of nucleic acids and methods of use thereof
WO2023230295A1 (en) 2022-05-25 2023-11-30 BioNTech SE Rna compositions for delivery of monkeypox antigens and related methods
CN119562807A (zh) 2022-05-30 2025-03-04 生物技术公司 用于递送核酸的复合物
TWI858802B (zh) * 2022-07-06 2024-10-11 南韓商綠十字股份有限公司 使用陽離子膽固醇用於核酸遞送的局部遞送的脂質納米顆粒
CA3263437A1 (en) 2022-07-29 2024-02-01 Fujifilm Corporation COMPOSITIONS AND METHODS FOR INHIBITING THE EXPRESSION OF THE SIGNAL REGULATOR ALPHA PROTEIN (SIRPα) GENE
WO2024037577A1 (en) * 2022-08-18 2024-02-22 Suzhou Abogen Biosciences Co., Ltd. Composition of lipid nanoparticles
WO2024057237A1 (en) 2022-09-16 2024-03-21 Pfizer Inc. Lipid nanoparticles
EP4342460A1 (en) 2022-09-21 2024-03-27 NovoArc GmbH Lipid nanoparticle with nucleic acid cargo
EP4637718A1 (en) * 2022-12-21 2025-10-29 Suzhou Abogen Biosciences Co., Ltd. Lipid nanoparticles comprising sterol-modified phospholipids
EP4642797A1 (en) 2022-12-28 2025-11-05 BioNTech SE Rna compositions targeting hiv
EP4410316A1 (en) * 2023-02-01 2024-08-07 4basebio UK Ltd Nanoparticles for delivery of nucleic acid cargos
AU2024217077A1 (en) * 2023-02-06 2025-09-18 University Of Tennessee Research Foundation Multi-functional lipid nanoparticles and uses thereof
WO2024205499A1 (en) * 2023-03-27 2024-10-03 Agency For Science, Technology And Research A compound for preparing lipid nanoparticles encapsulating an agent, nanoparticle composition comprising said compound and related methods thereof
WO2024259158A2 (en) * 2023-06-13 2024-12-19 Cornell University Lipid nanoparticles for peptide delivery and methods of making and using the same
WO2025027579A2 (en) 2023-08-03 2025-02-06 BioNTech SE Rna compositions targeting hiv
CN121866336A (zh) 2023-08-03 2026-04-14 百欧恩泰欧洲股份公司 靶向hiv的rna组合物
CN121752256A (zh) 2023-09-01 2026-03-27 诺沃阿克有限责任公司 具有核酸负载物和可电离脂质的脂质纳米颗粒
WO2025124711A1 (en) 2023-12-13 2025-06-19 BioNTech SE Glycolipid compositions
WO2025219570A1 (en) 2024-04-17 2025-10-23 Johannes Kepler Universität Linz Composition for inhibiting protein translocation and methods using the same
WO2025242657A1 (en) 2024-05-21 2025-11-27 Shape Biopharmaceuticals Ag Lipopeptide building blocks and aggregates
GB202408360D0 (en) 2024-06-11 2024-07-24 Cancer Research Tech Ltd Tumour sensitisation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3007955A1 (en) * 2015-12-10 2017-06-15 Modernatx, Inc. Lipid nanoparticles for delivery of therapeutic agents
AU2017286980B2 (en) * 2016-06-30 2023-10-26 Arbutus Biopharma Corporation Compositions and methods for delivering messenger RNA

Also Published As

Publication number Publication date
CA3137450A1 (en) 2020-10-29
CN114026233A (zh) 2022-02-08
US20220168222A1 (en) 2022-06-02
EP3959314A1 (en) 2022-03-02
WO2020219941A1 (en) 2020-10-29
EP3959314A4 (en) 2023-02-08
AU2020262437A1 (en) 2021-12-23
JP2022530018A (ja) 2022-06-27

Similar Documents

Publication Publication Date Title
EP3877521A4 (en) LIPID DNA NOPARTICLE FORMULATIONS
EP3877522A4 (en) LIPID DNA NOPARTICLE FORMULATIONS
EP3967649A4 (en) LIPIDNANOPARTICLES
DK4328309T3 (da) Lipidsammensætning
DK3532103T3 (da) Formuleringer af lipid-nanopartikler
EP3645767A4 (en) MAGNETIC NANOPARTICLE
EP2968510A4 (en) COMPOSITIONS OF NANOPARTICLES
EP4201400A4 (en) LIPID DNANOPARTICLES
DK3835287T3 (da) Kationisk lipid
JP2016502162A5 (OSRAM)
EP3863965C0 (en) LIQUID-EXFOLIATED NANOMATERIALS
EP3313381A4 (en) BIOMARKERS FOR NANOPARTICLE COMPOSITIONS
EP3959195C0 (en) THIOESTER CATIONIC LIPIDS
IL281425A (en) Nanoparticle formulations
EP3887350A4 (en) SOLID LIPID DNA NOPARTICLES OF CURCUMIN
IL283458A (en) Nanoparticles comprising tacrolimus
DK3946179T4 (da) Stomiposer
EP3668705C0 (en) ADDITIVE MANUFACTURING
EP3558864A4 (en) NANOPARTICLES
MA43648A (fr) Conjugués de nanoparticules
EP3986832A4 (en) Polyester polymer nanocomposites
EP3534909A4 (en) POLYMANANOPARTICLE
IL280640A (en) Nanoparticles for transfection
EP3830021A4 (en) Tetrahexahedra nanoparticles
EP3512503A4 (en) Liposomal formulations